Impact of genotypic susceptibility score on cART outcomes during primary HIV infection.
Andrea GiacomelliMassimiliano FabbianiIlaria De BenedettoSilvia NozzaEmanuele FocàBenedetto M CelesiaGiulia MarchettiCristina MussiniAndrea AntinoriGabriella d'EttorreGiordano MadedduAlessandra BanderaAntonio MuscatelloStefano RusconiPublished in: Journal of medical virology (2019)
To assess the impact of genotypic susceptibility score (GSS) on combined antiretroviral therapy (cART) outcomes during primary HIV infection (PHI) we retrospectively enrolled patients with PHI diagnosed between 2008 and 2015 at 9/24 Italian Network ACuTe HIV InfectiON centers. One hundred-seventy-six patients were enrolled. Of these, 55 (32.9%) patients started with more than three drugs and 11 (7.2%) started with a GSS < 3. Regimen's GSS (per 1 point increase) (adjusted odds ratio [aOR], 4.82; 95% confidence interval [CI], 1.62-14.28; P = .005) and baseline HIV-RNA (per 1 log10 increase) (aOR, 2.02; 95% CI, 1.09-3.73; P = .025) resulted associated with early cART initiation. In conclusion, regimen's GSS resulted to be associated to the time to cART initiation during PHI.
Keyphrases
- antiretroviral therapy
- hiv infected
- end stage renal disease
- human immunodeficiency virus
- hiv positive
- ejection fraction
- newly diagnosed
- chronic kidney disease
- hiv aids
- prognostic factors
- peritoneal dialysis
- type diabetes
- patient reported outcomes
- intensive care unit
- metabolic syndrome
- skeletal muscle
- drug induced
- acute respiratory distress syndrome
- hiv testing
- extracorporeal membrane oxygenation
- respiratory failure